Protalix Biotherapeutics, Inc. PLX 深 滬
等待開盤 08-21 09:30:00 美东时间
2.38
+0.030
+1.28%
華盛通- 最 高2.39
- 今 開2.32
- 成交量 38.50万股
- 最 低 2.3101
- 昨 收 2.35
- 總市值 1.92亿
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 1.5201
- 委 比 -89.90%
- 總股本 8057.16万
- 歷史最高 77.00
- 量 比 0.40
- 振 幅 3.40%
- 歷史最低 0.70
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多普罗塔利斯生物制药 (PLX) 2026年第二季度业绩电话会议：Elfabrio驱动营收增长
受Elfabrio推动增长，Protalix BioTherapeutics 2026年第二季度营收增长26.8%至1990万美元，同时管理层重申了其全年业绩展望。
08-14 08:35
Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of $19.896 million which beat the analyst consensus estimate of $12.931 million by 53.86 percent. This is a 2...
08-12 18:51
Protalix BioTherapeutics Q2 Earnings Preview
Protalix BioTherapeutics (PLX) is scheduled to announce Q2 earnings results on Wednesday, August 12th, before market open. The consensus EPS estimate is -$0.01, and the consensus revenue estimate is $...
08-11 23:10
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone
Earnings Call Insights: Protalix BioTherapeutics (PLX) Q1 2026 Management View “During the quarter, we received a $25 million milestone from Chiesi, following the European Commission approval of Elfab...
05-13 23:52
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Protalix BioTherapeutics Q1 EPS $0.05 Misses $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 200 percent increase over losses of $(0.05) per share
05-13 19:02
Protalix BioTherapeutics give Q1 results
Protalix BioTherapeutics press release (PLX): Q1 GAAP EPS of $0.22 Revenue of $33.75M (+233.8% Y/Y) The Company reaffirms its previously stated 2026 revenue expectations: Total revenue in 2026 to ra...
05-13 18:53
Protalix BioTherapeutics Q1 Earnings Preview
Protalix BioTherapeutics (PLX) is scheduled to announce Q1 earnings results on Wednesday, May 13th, before market open. The consensus EPS estimate is -$0.01, and the consensus revenue estimate is $11....
05-13 02:07
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
